Allarity Therapeutics vs Clene
Allarity Therapeutics reported revenue of $0 million in fiscal 2025, 1.5 times Clene's $0 million in fiscal 2025. Allarity Therapeutics had an operating margin of -3939.1%, against -11541.5% at Clene. Free cash flow was −$15 million at Allarity Therapeutics and −$19 million at Clene.
Side by side
| Allarity Therapeutics | Clene | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $0M | $0M |
| Revenue growth | — | −41.5% |
| Revenue growth a year, last 5 years | — | 0.0% |
| Gross margin | — | 78.5% |
| Operating margin | −3,939.1% | −11,541.5% |
| Net margin | −3,509.7% | −13,086.5% |
| Free cash flow | −$15M | −$19M |
| Free cash flow margin | −4,633.8% | −9,292.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $3M | $0M |
| Change in diluted share count | 794.8% | 41.8% |
| Last close | $0.86 | $3.50 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $250,904, sold $5.8 million |
| Piotroski F-score | — | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Allarity TherapeuticsClene
Operating margin
Percent of revenue
Allarity TherapeuticsClene
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Allarity TherapeuticsClene
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Allarity Therapeutics and Clene pages.